40265_2022_1684_MOESM1_ESM_correctted.pdf (146.72 kB)
Download file

Molnupiravir: First Approval

Download (146.72 kB)
online resource
posted on 09.02.2022, 03:00 authored by Yahiya Y. Syed

Declarations

Funding The preparation of this review was not supported by any external funding.

Authorship and Conflict of interest Yahiya Y. Syed is a salaried employee of Adis International Ltd/Springer Nature, and declares no relevant conflicts of interest. All authors contributed to the review and are responsible for the article content.

Ethics approval, Consent to participate, Consent to publish, Availability of data and material, Code availability not applicable

Additional information about this Adis Drug Review can be found here

Abstract

Molnupiravir ( Lagevrio®) is an orally-administered antiviral prodrug that inhibits replication of RNA viruses through viral error induction. It is being developed by Merck and Ridgeback Biotherapeutics for the prevention and treatment of Coronavirus disease 2019 (COVID-19). Molnupiravir received its first approval on 4 November 2021 in the UK for the treatment of mild to moderate COVID-19 in adults with a positive severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) diagnostic test and who have at least one risk factor for developing severe illness. Molnupiravir is filed for approval and has emergency use authorization for the treatment of COVID-19 in several countries, including the USA and those in the EU. This article summarizes the milestones in the development of molnupiravir leading to this first approval for COVID-19.

© Springer Nature Switzerland AG 2021

History

Usage metrics

Read the peer-reviewed publication

Categories

Exports